Home > Stephanie J Nahas, EAN 2020 – Anti-CGRP mAb Efficacy in Patients ≥60 With Episodic/Chronic Migraine
Headache Disorders

Stephanie J Nahas, EAN 2020 – Anti-CGRP mAb Efficacy in Patients ≥60 With Episodic/Chronic Migraine

Published Online: May 29th 2020

Stephanie J Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) kindly took the time to discuss with us pooled findings from phase 3 randomised controlled trials with fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treatment, specifically in older patients (≥60 years) with episodic or chronic migraine.

Questions
1. How does the clinical phenotype of migraine differ in patients aged 60 and over compared with that in younger patients? (0:05)
2. What are the main unmet needs in the treatment of episodic or chronic migraine in this patient group? (
0:57)
3. How extensively has fremanezumab been studied in this patient group? (
2:01)
4. What were the efficacy and safety findings of your pooled analysis? (
3:00)
5. Among older patients, which are likely to benefit most from fremanezumab and in whom is it contraindicated? (
4:46)

Speaker disclosure: Stephanie J Nahas has served on an advisory board, as a speaker, or as a consultant for Allergan, Amgen/Novartis, Biohaven, electroCore, Eli Lilly, Impel, Supernus, Teva Pharmaceuticals, Theranica, and Zosano.

Support: Interview and filming supported by Touch Medical Media.

Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.

Related Videos In Headache Disorders
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar